Boston Scientific (BSX) says it has received FDA clearance for the two validated manufacturing...

|About: Boston Scientific Corporation (BSX)|By:, SA News Editor

Boston Scientific (BSX) says it has received FDA clearance for the two validated manufacturing changes affecting its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its Cognis CRT-Ds and Teligen ICDs. Shares +7.1% AH. (PR)